[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335297-105":59,"doc-detail-335297-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","repurposing-metabolic-regulators-antidiabetic-drugs-as-anticancer-agents","Repurposing metabolic regulators: antidiabetic drugs as anticancer agents","","Drug repurposing in cancer leverages medications originally developed for other conditions, aiming to reduce cost and shorten development timelines while lowering the risk of adverse effects compared with de novo discovery. Yet drug classes do not always match patient needs or support long-term use. Metabolic reprogramming is a cancer hallmark, motivating metabolic regulators—especially antidiabetic drugs—as candidate therapeutics. The review surveys metformin, sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, thiazolidinediones, and α-glucosidase inhibitors across cancer types, noting heterogeneous evidence and the need for further mechanism-focused and clinical validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/repurposing-metabolic-regulators-antidiabetic-drugs-as-anticancer-agents/335297/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/repurposing-metabolic-regulators-antidiabetic-drugs-as-anticancer-agents/335297.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main idea behind repurposing antidiabetic drugs for cancer therapy?","Question",{"text":112,"@type":113},"The review explains that repurposing uses existing drugs with established safety profiles for new anticancer purposes. It is motivated by cancer-related metabolic reprogramming and the ability of metabolic regulators to influence tumor biology.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which antidiabetic drugs are discussed as having potential anticancer effects?",{"text":117,"@type":113},"The review emphasizes metformin and also covers sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, thiazolidinediones, and α-glucosidase inhibitors, evaluating their evidence across different cancer types.",{"name":119,"@type":110,"acceptedAnswer":120},"Are the effects of antidiabetic drugs on cancer risk consistent across all drug classes?",{"text":121,"@type":113},"No. The review reports heterogeneous responses: metformin may show anticancer properties, sulfonylureas and thiazolidinediones do not show consistent activity, while SGLT2 inhibitors and DPP-4 inhibitors show some potential benefits. It also notes concerns with GLP-1 receptor agonists regarding associations with certain cancer risks.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335297,1790142425,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Dhas et al. Molecular Biomedicine (2024) 5:40 [https://doi.org/10.1186/s43556-024-00204-z](https://doi.org/10.1186/s43556-024-00204-z)  \nMolecular Biomedicine  \n REVIEW Open Access  \nRepurposing metabolic regulators: antidiabetic drugs as anticancer agents  \nYogita Dhas 1, Nupur Biswas1,2* , Divyalakshmi M. R.1, Lawrence D. Jones2 and Shashaanka Ashili2  \nAbstract  \nDrug repurposing in cancer taps into the capabilities of existing drugs, initially designed for other ailments, as potential cancer treatments. It offers several advantages over traditional drug discovery, including reduced costs, reduced development timelines, and a lower risk of adverse effects. However, not all drug classes align seamlessly with a patient’s condition or long-term usage. Hence, repurposing of chronically used drugs presents a more attractive option. On the other hand, metabolic reprogramming being an important hallmark of cancer paves the metabolic regulators as possible cancer therapeutics. This review emphasizes the importance and offers current insights into the repurposing of antidiabetic drugs, including metformin, sulfonylureas, sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), thiazolidinediones (TZD), and α-glucosidase inhibitors, against various types of cancers. Antidiabetic drugs, regulating metabolic pathways have gained considerable attention in cancer research. The literature reveals a complex relationship between antidiabetic drugs and cancer risk. Among the antidiabetic drugs, metformin may possess anti-cancer properties, potentially reducing cancer cell proliferation, inducing apoptosis, and enhancing cancer cell sensitivity to chemotherapy. However, other antidiabetic drugs have revealed heterogeneous responses. Sulfonylureas and TZDs have not demonstrated consistent anti-cancer activity, while SGLT2 inhibitors and DPP-4 inhibitors have shown some potential benefits. GLP-1RAs have raised concerns due to possible associations with an increased risk of certain cancers. This review highlights that further research is warranted to elucidate the mechanisms underlying the potential anti-cancer effects of these drugs and to establish their efficacy and safety in clinical settings.  \nKeywords Diabetes mellitus, Cancer, Drug repurposing, Antidiabetic drugs  \nIntroduction  \nThe evolving relationship between metabolic disordersand oncogenesis signifies a paradigm shift extending beyond traditional disease management. Diabetes and cancer, both prevalent and impactful, are on the rise globally [1–3]. Diabetes, characterized by elevated blood sugar levels, affects a substantial global population, with approximately 536.6 million individuals in 2021, projected to rise to 783.2 million by 2045 [4]. Concurrently,  \n*Correspondence: Nupur Biswas  \n[nupur@rhenix.org](nupur@rhenix.org); [nupurbiswas@gmail.com](nupurbiswas@gmail.com)  \n1 Rhenix Lifesciences, Hyderabad 500038, Telangana, India  \n2 CureScience, 5820 Oberlin Dr, Suite 202, San Diego, CA 92121, USA  \ncancer stands as a primary contributor to global mortality, with GLOBOCAN 2022 estimating 20 million new cases and 9.7 million deaths in 2022 [5]. This dual escalation of diabetes and cancer underlines the pressing need for comprehensive research and effective strategies to address the growing burden of diabetes and cancer worldwide. The interplay between diabetes and cancer is a complex and multifaceted relationship drawing increased attention in oncology and endocrinology. It involves intricate associations at molecular, metabolic, and epidemiological levels [2, 3]. It is essential to acknowledge this dynamic interplay because shared risk factors and biological processes mutually shape and influence their interconnected growth. The coexistence of diabetes and cancer often stems from common risk  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4","cbCainGFi9mXuDgw","https://ap.wps.com/l/cbCainGFi9mXuDgw","pdf",1831156,"English","# Abstract\n# Introduction\n## Diabetes and cancer: rising global burden\n## Molecular links: insulin signaling, AMPK, and mTOR","[{\"question\":\"What is the main idea behind repurposing antidiabetic drugs for cancer therapy?\",\"answer\":\"The review explains that repurposing uses existing drugs with established safety profiles for new anticancer purposes. It is motivated by cancer-related metabolic reprogramming and the ability of metabolic regulators to influence tumor biology.\"},{\"question\":\"Which antidiabetic drugs are discussed as having potential anticancer effects?\",\"answer\":\"The review emphasizes metformin and also covers sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, thiazolidinediones, and α-glucosidase inhibitors, evaluating their evidence across different cancer types.\"},{\"question\":\"Are the effects of antidiabetic drugs on cancer risk consistent across all drug classes?\",\"answer\":\"No. The review reports heterogeneous responses: metformin may show anticancer properties, sulfonylureas and thiazolidinediones do not show consistent activity, while SGLT2 inhibitors and DPP-4 inhibitors show some potential benefits. It also notes concerns with GLP-1 receptor agonists regarding associations with certain cancer risks.\"}]","Repurposing metabolic regulators: antidiabetic drugs as anticancer agents | PDF",1790010417,48]